JP2002541213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002541213A5 JP2002541213A5 JP2000610510A JP2000610510A JP2002541213A5 JP 2002541213 A5 JP2002541213 A5 JP 2002541213A5 JP 2000610510 A JP2000610510 A JP 2000610510A JP 2000610510 A JP2000610510 A JP 2000610510A JP 2002541213 A5 JP2002541213 A5 JP 2002541213A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- fsp
- variant
- effective amount
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 description 89
- 210000004072 lung Anatomy 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 8
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000002685 pulmonary effect Effects 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009450 sialylation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12912199P | 1999-04-13 | 1999-04-13 | |
| US60/129,121 | 1999-04-13 | ||
| US13009999P | 1999-04-20 | 1999-04-20 | |
| US60/130,099 | 1999-04-20 | ||
| PCT/US2000/009869 WO2000061178A1 (en) | 1999-04-13 | 2000-04-13 | Pulmonary administration of dry powder formulations for treating infertility |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002541213A JP2002541213A (ja) | 2002-12-03 |
| JP2002541213A5 true JP2002541213A5 (enExample) | 2007-06-07 |
Family
ID=26827234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000610510A Withdrawn JP2002541213A (ja) | 1999-04-13 | 2000-04-13 | 不妊症の処置のための乾燥粉末処方物の肺投与 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7112341B1 (enExample) |
| EP (1) | EP1169053A1 (enExample) |
| JP (1) | JP2002541213A (enExample) |
| AU (1) | AU779869B2 (enExample) |
| CA (1) | CA2369262A1 (enExample) |
| HK (1) | HK1042234A1 (enExample) |
| TW (1) | TWI277425B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1188111C (zh) * | 1999-10-29 | 2005-02-09 | 耐科塔医药公司 | 分散性得到改进的干粉组合物 |
| EP1631496B1 (en) * | 2003-04-28 | 2014-02-26 | Medical Instill Technologies, Inc. | Container with valve assembly for filling and dispensing substances, and apparatus and method for filling |
| ME01043B (me) * | 2004-11-09 | 2005-11-08 | Ares Trading Sa | Metode za prećišćavanje fsh-a |
| US8604175B2 (en) * | 2005-12-09 | 2013-12-10 | Ares Trading S.A. | Method for purifying FSH or a FSH mutant |
| EP2013113B1 (en) * | 2006-04-24 | 2018-03-21 | Medical Instill Technologies, Inc. | Needle penetrable and resealable lyophilization device and related method |
| CN101848733A (zh) * | 2007-07-13 | 2010-09-29 | 艾博特生物技术有限公司 | 用于肺部给予TNFα抑制剂的方法和组合物 |
| RS64039B1 (sr) | 2008-11-10 | 2023-04-28 | Alexion Pharma Inc | Metode i kompozicije za lečenje poremećaja povezanih sa komplementom |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| EP2523976B1 (en) | 2010-01-11 | 2018-04-25 | Alexion Pharmaceuticals, Inc. | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
| KR101800913B1 (ko) | 2010-04-30 | 2017-12-20 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-c5a 항체들과 이 항체들을 이용하는 방법 |
| ES2729549T3 (es) * | 2011-08-02 | 2019-11-04 | Alfasigma Spa | Composición farmacéutica de avidina oxidada adecuada para la inhalación |
| PT2880164T (pt) * | 2012-07-30 | 2019-06-05 | Trophogen Inc | Superagonistas de ação prolongada de hormonas glicoproteicas |
| US10457713B2 (en) | 2012-07-30 | 2019-10-29 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
| BR112016009962A2 (pt) | 2013-11-05 | 2017-12-05 | Trophogen Inc | superagonistas de ação prolongada de hormônio glicoproteico |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| ES2965486T3 (es) | 2017-07-27 | 2024-04-15 | Alexion Pharma Inc | Formulaciones de anticuerpos anti-C5 de alta concentración |
| KR20200070355A (ko) | 2017-10-26 | 2020-06-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여 |
| US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
| ES2996257T3 (en) | 2018-05-31 | 2025-02-12 | Alexion Pharma Inc | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| EP3802603A1 (en) | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| WO2020006266A1 (en) | 2018-06-28 | 2020-01-02 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| JP2021534111A (ja) | 2018-08-10 | 2021-12-09 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法 |
| US12240893B2 (en) | 2018-10-30 | 2025-03-04 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) |
| US12433938B2 (en) | 2019-12-09 | 2025-10-07 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| WO2022087229A1 (en) * | 2020-10-23 | 2022-04-28 | Alexion Pharmaceuticals, Inc. | Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase |
| AU2022218782A1 (en) | 2021-02-12 | 2023-08-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2224175B1 (enExample) | 1973-04-04 | 1978-04-14 | Isf Spa | |
| IT1017153B (it) | 1974-07-15 | 1977-07-20 | Isf Spa | Apparecchio per inalazioni |
| US4234571A (en) | 1979-06-11 | 1980-11-18 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| SE438261B (sv) | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
| HU185535B (en) | 1982-05-25 | 1985-02-28 | Mta Koezponti Hivatala | Process for preparing new gonadoliberin derivatives |
| GB8314308D0 (en) | 1983-05-24 | 1983-06-29 | Matburn Holdings Ltd | Medical administration devices |
| US5639639A (en) | 1983-11-02 | 1997-06-17 | Genzyme Corporation | Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof |
| US4840896A (en) | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
| US5156957A (en) | 1983-11-02 | 1992-10-20 | Genzyme Corporation | Follicle stimulating hormone |
| EP0578328B1 (en) | 1983-11-02 | 1999-12-29 | Applied Research Systems ARS Holding N.V. | Material and methods for the production of a heterodimeric human LH with a Met42 Val55 alpha subunit |
| US4923805A (en) | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
| US4589402A (en) | 1984-07-26 | 1986-05-20 | Serono Laboratories, Inc. | Method of in vitro fertilization |
| US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| DE229810T1 (de) | 1985-07-09 | 1987-11-05 | Quadrant Bioresources Ltd., Soulbury, Leighton Buzzard, Bedfordshire | Beschuetzung von proteinen und aehnlichem. |
| EP0290269A3 (en) * | 1987-05-06 | 1989-08-09 | Cyberfluor Inc. | Immunoassay methods and reagents and methods for producing the latter |
| IT1206302B (it) | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
| ATE148171T1 (de) | 1989-02-21 | 1997-02-15 | Univ Washington | Modifizierte formen von fortpflanzungshormonen |
| GB8909891D0 (en) | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
| US5384132A (en) | 1990-03-20 | 1995-01-24 | Akzo N.V. | Stabilized gonadotropin containing preparations |
| IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| US5270057A (en) | 1990-03-20 | 1993-12-14 | Akzo N.V. | Stabilized gonadotropin containing preparations |
| US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
| IT1243344B (it) | 1990-07-16 | 1994-06-10 | Promo Pack Sa | Inalatore plurimonodose per medicamenti in polvere |
| CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| IT1250075B (it) | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
| US5320094A (en) | 1992-01-10 | 1994-06-14 | The Johns Hopkins University | Method of administering insulin |
| US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US5672581A (en) | 1993-01-29 | 1997-09-30 | Aradigm Corporation | Method of administration of insulin |
| US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
| US5994314A (en) | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
| IS1796B (is) | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| IS1736B (is) | 1993-10-01 | 1999-12-30 | Astra Ab | Aðferð og tæki sem stuðla að aukinni samloðun agna |
| US5388572A (en) | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
| US6238890B1 (en) * | 1994-02-18 | 2001-05-29 | Washington University | Single chain forms of the glycoprotein hormone quartet |
| US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| SE9404468D0 (sv) * | 1994-12-22 | 1994-12-22 | Astra Ab | Powder formulations |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| ES2237767T3 (es) | 1995-04-14 | 2005-08-01 | Nektar Therapeutics | Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada. |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US5826633A (en) | 1996-04-26 | 1998-10-27 | Inhale Therapeutic Systems | Powder filling systems, apparatus and methods |
| FR2754450B1 (fr) | 1996-10-11 | 1998-12-31 | 3X Engineering | Materiau support de microcapsules |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| US5990288A (en) * | 1997-10-21 | 1999-11-23 | Vitro Diagnostics, Inc. | Method for purifying FSH |
| ATE233097T1 (de) | 1997-11-07 | 2003-03-15 | Chiron Corp | Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung |
| PL346127A1 (en) | 1998-07-23 | 2002-01-28 | Lilly Co Eli | Fsh and fsh variant formulations, products and methods |
-
2000
- 2000-04-13 HK HK02103235.7A patent/HK1042234A1/zh unknown
- 2000-04-13 US US09/958,722 patent/US7112341B1/en not_active Expired - Fee Related
- 2000-04-13 TW TW089106884A patent/TWI277425B/zh not_active IP Right Cessation
- 2000-04-13 CA CA002369262A patent/CA2369262A1/en not_active Abandoned
- 2000-04-13 EP EP00920245A patent/EP1169053A1/en not_active Withdrawn
- 2000-04-13 JP JP2000610510A patent/JP2002541213A/ja not_active Withdrawn
- 2000-04-13 AU AU40820/00A patent/AU779869B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002541213A5 (enExample) | ||
| US6479049B1 (en) | Methods and compositions for the dry powder formulation of interferons | |
| US6080721A (en) | Pulmonary delivery of active fragments of parathyroid hormone | |
| US6582728B1 (en) | Spray drying of macromolecules to produce inhaleable dry powders | |
| US6509006B1 (en) | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments | |
| US20050203002A1 (en) | Sustained release compositions for delivery of pharmaceutical proteins | |
| JPH10511090A (ja) | 副甲状腺ホルモン，ｐｔｈ含有吸入用治療製剤 | |
| US20030086877A1 (en) | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments | |
| JP2005506956A (ja) | 長時間作用性ｇｌｐ−１製剤 | |
| US20030035778A1 (en) | Methods and compositions for the dry powder formulation of interferon | |
| JPWO2020055824A5 (enExample) | ||
| KR20130055665A (ko) | 소 과립구 콜로니 자극 인자 및 그의 변이체를 위한 제제 |